DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Solaraze (Diclofenac Sodium Topical) - Side Effects and Adverse Reactions

 
 



ADVERSE REACTIONS

Of the 423 patients evaluable for safety in adequate and well-controlled trials, 211 were treated with Solaraze® drug product and 212 were treated with a vehicle gel. Eighty-seven percent (87%) of the Solaraze®-treated patients (183 patients) and 84% of the vehicle-treated patients (178 patients) experienced one or more adverse events (AEs) during the studies. The majority of these reactions were mild to moderate in severity and resolved upon discontinuation of therapy.

Of the 211 patients treated with Solaraze®, 172 (82%) experienced AEs involving skin and the application site compared to 160 (75%) vehicle-treated patients. Application site reactions (ASRs) were the most frequent AEs in both Solaraze®-and vehicle-treated groups. Of note, four reactions, contact dermatitis, rash, dry skin and exfoliation (scaling) were significantly more prevalent in the Solaraze® group than in the vehicle-treated patients.

Eighteen percent of Solaraze®-treated patients and 4% of vehicle-treated patients discontinued from the clinical trials due to adverse events (whether considered related to treatment or not). These discontinuations were mainly due to skin irritation or related cutaneous adverse reactions.

Table 1 below presents the AEs reported at an incidence of >1% for patients treated with either Solaraze® Gel or vehicle (60- and 90-day treatment groups) during the phase 3 studies.

Table 1. Adverse Events Reported (>1% in Any Treatment Group) During Solaraze® Phase 3 Clinical Trials Incidences for 60-Day and 90-Day Treatments
60-day Treatment 90-day Treatment
Solaraze® (%) Gel Vehicle (%) Solaraze® (%) Gel Vehicle (%)
N=48 N=49 N=114 N=114
BODY AS A WHOLE 21 20 20 18
Abdominal Pain 2 0 1 0
Accidental Injury 0 0 4 2
Allergic Reaction 0 0 1 3
Asthenia 0 0 2 0
Back Pain 4 0 2 2
Chest Pain 2 0 1 0
Chills 0 2 0 0
Flu Syndrome 10 6 1 4
Headache 0 6 7 6
Infection 4 6 4 5
Neck Pain 0 0 2 0
Pain 2 0 2 2
CARDIOVASCULAR SYSTEM 2 4 3 1
Hypertension 2 0 1 0
Migraine 0 2 1 0
Phlebitis 0 2 0 0
DIGESTIVE SYSTEM 4 0 6 8
Constipation 0 0 0 2
Diarrhea 2 0 2 3
Dyspepsia 2 0 3 4
METABOLIC AND NUTRITIONAL DISORDERS 2 8 7 2
Creatine Phosphokinase Increased 0 0 4 1
Creatinine Increased 2 2 0 1
Edema 0 2 0 0
Hypercholesteremia 0 2 1 0
Hyperglycemia 0 2 1 0
SGOT Increased 0 0 3 0
SGPT Increased 0 0 2 0
MUSCULOSKELETAL SYSTEM 4 0 3 4
Arthralgia 2 0 0 2
Arthrosis 2 0 0 0
Myalgia 2 0 3 1
NERVOUS SYSTEM 2 2 2 5
Anxiety 0 2 0 1
Dizziness 0 0 0 4
Hypokinesia 2 0 0 0
RESPIRATORY SYSTEM 8 8 7 6
Asthma 2 0 0 0
Dyspnea 2 0 2 0
Pharyngitis 2 8 2 4
Pneumonia 2 0 0 1
Rhinitis 2 2 2 2
Sinusitis 0 0 2 0
SKIN AND APPENDAGES 75 86 86 71
Acne 0 2 0 1
Application Site Reaction 75 71 84 70
    Acne 0 4 1 0
    Alopecia 2 0 1 1
    Contact Dermatitis 19 4 33 4
    Dry Skin 27 12 25 17
    Edema 4 0 3 0
    Exfoliation 6 4 24 13
    Hyperesthesia 0 0 3 1
    Pain 15 22 26 30
    Paresthesia 8 4 20 20
    Photosensitivity Reaction 0 2 3 0
    Pruritus 31 59 52 45
    Rash 35 20 46 17
    Vesiculobullous Rash 0 0 4 1
Contact Dermatitis 2 0 0 0
Dry Skin 0 4 3 0
Herpes Simplex 0 2 0 0
Maculopapular Rash 0 2 0 0
Pain 2 2 1 0
Pruritus 4 6 4 1
Rash 2 10 4 0
Skin Carcinoma 0 6 2 2
Skin Nodule 0 2 0 0
Skin Ulcer 2 0 1 0
SPECIAL SENSES 2 0 4 2
Conjunctivitis 2 0 4 1
Eye Pain 0 2 2 0
UROGENITAL SYSTEM 0 0 4 5
Hematuria 0 0 2 1
OTHER 0 0 0 3
Procedure 0 0 0 3

Skin and Appendages Adverse Events Reported for Solaraze ® at Less Than 1% Incidence in the Phase 3 Studies: skin hypertrophy, paresthesia, seborrhea, urticaria, application site reactions (skin carcinoma, hypertonia, skin hypertrophy lacrimation disorder, maculopapular rash, purpuric rash, vasodilation).

Adverse Reactions Reported for Oral Diclofenac Dosage Form (not topical Solaraze ® Gel): *Incidence greater than 1% marked with asterisk.

Body as a Whole: abdominal pain or cramps*, headache*, fluid retention*, abdominal distention*, malaise, swelling of lips and tongue, photosensitivity, anaphylaxis, anaphylactoid reactions, chest pain.

Cardiovascular: hypertension, congestive heart failure, palpitations, flushing, tachycardia, premature ventricular contractions, myocardial infarction, hypotension.

Digestive: diarrhea*, indigestion*, nausea*, constipation*, flatulence*, liver test abnormalities*, PUB*, i.e., peptic ulcer, with or without bleeding and/or perforation, or bleeding without ulcer, vomiting, jaundice, melena, esophageal lesions, aphthous stomatitis, dry mouth and mucous membranes, bloody diarrhea, hepatitis, hepatic necrosis, cirrhosis, hepatorenal syndrome, appetite change, pancreatitis with or without concomitant hepatitis, colitis, intestinal perforation.

Hemic and Lymphatic: hemoglobin decrease, leukopenia, thrombocytopenia, eosinophilia, hemolytic anemia, aplastic anemia, agranulocytosis, purpura, allergic purpura, bruising.

Metabolic and Nutritional Disorders: azotemia, hypoglycemia, weight loss.

Nervous System: dizziness*, insomnia, drowsiness, depression, diplopia, anxiety, irritability, aseptic meningitis, convulsions, paresthesia, memory disturbance, nightmares, tremor, tic, abnormal coordination, disorientation, psychotic reaction.

Respiratory: epistaxis, asthma, laryngeal edema, dyspnea, hyperventilation, edema of pharynx.

Skin and Appendages: rash*, pruritus*, alopecia, urticaria, eczema, dermatitis, bullous eruption, erythema multiforme major, angioedema, Stevens-Johnson syndrome, excess perspiration, exfoliative dermatitis.

Special Senses: tinnitus*, blurred vision, taste disorder, reversible and irreversible hearing loss, scotoma, vitreous floaters, night blindness, amblyopia.

Urogenital: nephrotic syndrome, proteinuria, oliguria, interstitial nephritis, papillary necrosis, acute renal failure, urinary frequency, nocturia, hematuria, impotence, vaginal bleeding.



REPORTS OF SUSPECTED SOLARAZE SIDE EFFECTS / ADVERSE REACTIONS

Below is a sample of reports where side effects / adverse reactions may be related to Solaraze. The information is not vetted and should not be considered as verified clinical evidence.

Possible Solaraze side effects / adverse reactions in 90 year old male

Reported by a health professional (non-physician/pharmacist) from Germany on 2012-04-13

Patient: 90 year old male

Reactions: Headache, Hallucination

Suspect drug(s):
Solaraze



Possible Solaraze side effects / adverse reactions in 68 year old male

Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-04-24

Patient: 68 year old male

Reactions: Swelling Face, Erythema

Adverse event resulted in: hospitalization

Suspect drug(s):
Solaraze
    Dosage: ;bid;top;bid;top
    Administration route: Topical
    Indication: Product Used FOR Unknown Indication
    Start date: 2012-03-22
    End date: 2012-03-23

Solaraze
    Dosage: ;bid;top;bid;top
    Administration route: Topical
    Indication: Product Used FOR Unknown Indication
    Start date: 2011-01-01
    End date: 2011-01-01



Possible Solaraze side effects / adverse reactions in 64 year old male

Reported by a health professional (non-physician/pharmacist) from Switzerland on 2012-04-24

Patient: 64 year old male

Reactions: Application Site Exfoliation, Application Site Erythema

Suspect drug(s):
Solaraze



See index of all Solaraze side effect reports >>

Drug label data at the top of this Page last updated: 2012-12-13

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017